Split History
ETFs Holding ADAP »    ADAP Historical Stock Prices »
Video: What is a Stock Split?

If the video does not load after a few moments, Upgrade to the Latest Flash Player.
Adaptimmune Therapeutics is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapy products based on Co.'s proprietary SPEAR (Specific Peptide Enhanced Affinity Receptor) T-cell platform. Co. has developed a proprietary platform to identify cancer targets, find and engineer T-cell receptors (TCRs), and produce TCR therapeutic candidates for administration to patients. Co. has three SPEAR T-cells in clinical trials which are directed to cancer testis antigens, NY-ESO-1, MAGE-A4 and MAGE-A10. These SPEAR T-cells are directed in multiple disease indications including non-small cell lung cancer, melanoma, urothelial (bladder) cancers and head and neck cancers. According to our ADAP split history records, Adaptimmune Therapeutics PLC has had 1 split.
ADAP split history picture
Adaptimmune Therapeutics PLC (ADAP) has 1 split in our ADAP split history database. The split for ADAP took place on March 31, 2000. This was a 2 for 1 split, meaning for each share of ADAP owned pre-split, the shareholder now owned 2 shares. For example, a 1000 share position pre-split, became a 2000 share position following the split.

When a company such as Adaptimmune Therapeutics PLC splits its shares, the market capitalization before and after the split takes place remains stable, meaning the shareholder now owns more shares but each are valued at a lower price per share. Often, however, a lower priced stock on a per-share basis can attract a wider range of buyers. If that increased demand causes the share price to appreciate, then the total market capitalization rises post-split. This does not always happen, however, often depending on the underlying fundamentals of the business. Looking at the ADAP split history from start to finish, an original position size of 1000 shares would have turned into 2000 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Adaptimmune Therapeutics PLC shares, starting with a $10,000 purchase of ADAP, presented on a split-history-adjusted basis factoring in the complete ADAP split history. ADAP split adjusted history picture

Growth of $10,000.00
Without Dividends Reinvested

Start date: 05/06/2015
End date: 12/14/2018
Start price/share: $16.00
End price/share: $5.16
Dividends collected/share: $0.00
Total return: -67.75%
Average Annual Total Return: -26.90%
Starting investment: $10,000.00
Ending investment: $3,225.61
Years: 3.61
Date Ratio
03/31/20002 for 1
Diffusion Pharmaceuticals Inc. (DFFN)
Tonix Pharmaceuticals Holding Corp. (TNXP)
SPI Energy Co., Ltd. (SPI)
Spirit Realty Capital, Inc. (SRC)
ReShape Lifesciences Inc. (RSLS)
Churchill Downs Incorporated (CHDN)
Rollins, Inc. (ROL)
Globus Maritime Limited (GLBS)
Regulus Therapeutics Inc. (RGLS)
Neonode Inc. (NEON)
More latest stock splits »
Latest mega mergers »
Latest stock buybacks »

ADAP Split History | www.SplitHistory.com | Copyright © 2013 - 2018, All Rights Reserved

Nothing in www.SplitHistory.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. Split history database is not guaranteed to be complete or free of errors. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Service. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.